Apellis Pharmaceuticals (NASDAQ: APLS) has recently received a number of price target changes and ratings updates: 8/30/2023 – Apellis Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock. 8/29/2023 – Apellis Pharmaceuticals had its price target raised by analysts at Citigroup […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) CEO Cedric Francois sold 150,000 shares of the stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $41.75, for a total transaction of $6,262,500.00. Following the sale, the chief executive officer now directly owns 424,655 shares of […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at Needham & Company LLC in a note issued to investors on Wednesday, Benzinga reports. They presently have a $60.00 price target on the stock. Needham & Company LLC’s target price suggests a potential upside of 42.15% from the […]
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price boosted by Citigroup from $45.00 to $54.00 in a research report sent to investors on Tuesday morning, MarketBeat reports. The brokerage currently has a buy rating on the stock. APLS has been the subject of several other research reports. Wedbush reiterated a neutral rating and […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its price target boosted by investment analysts at Stifel Nicolaus from $60.00 to $65.00 in a research report issued on Tuesday, MarketBeat reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 60.06% from the company’s […]